He Jin-Shui, Huang Zhong-Ling, Yang Hong, Weng Kai-Zhi, Zhu Shao-Bo
Department of Neonatology, Zhangzhou Municipal Hospital Affiliated to Fujian Medical University, Zhangzhou, Fujian 363000, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2008 Oct;10(5):586-8.
To evaluate the effect of the early use of recombinant human erythropoietin (rhu-EPO) on neurobehavioral development in preterm infants.
Forty-four preterm infants (30 males and 14 females) were randomly divided into two groups: Rhu-EPO treatment and untreated control (n=22 each). From postnatal day 7, the Rhu-EPO treatment group received intravenous rhu-EPO (250 IU/kg3 times weekly) for 4 weeks. A Neonatal Behavioral Neurological Assessment (NBNA) was performed at 40 weeks of corrected gestational age. A Gesell Development Schedule was used to evaluate neurological development 6 and 12 months after birth.
The NBNA score in the rhu-EPO treatment group (36.20+/-0.75) was significantly higher than that in the control group (34.40+/-1.05) at 40 weeks of corrected gestational age (P<0.05). The developmental quotient of fine motor in the rhu-EPO treatment group was significantly higher than that in the control group 6 months after birth (P<0.05). By 12 months after birth, the developmental quotient of gross motor, fine motor and language in the rhu-EPO treatment group was significantly higher than that in the control group (P<0.05).
Early use of Rhu-EPO can promote neurobehavioral development in preterm infants.
评估早期使用重组人促红细胞生成素（rhu-EPO）对早产儿神经行为发育的影响。
44例早产儿（男30例，女14例）随机分为两组：rhu-EPO治疗组和未治疗对照组（每组22例）。从出生后第7天起，rhu-EPO治疗组接受静脉注射rhu-EPO（250 IU/kg，每周3次），共4周。在矫正胎龄40周时进行新生儿行为神经评定（NBNA）。出生后6个月和12个月时使用盖塞尔发育量表评估神经发育情况。
矫正胎龄40周时，rhu-EPO治疗组的NBNA评分（36.20±0.75）显著高于对照组（34.40±1.05）（P<0.05）。出生后6个月，rhu-EPO治疗组的精细运动发育商显著高于对照组（P<0.05）。出生后12个月时，rhu-EPO治疗组的大运动、精细运动和语言发育商均显著高于对照组（P<0.05）。
早期使用rhu-EPO可促进早产儿的神经行为发育。
